Orthocell Ltd
OCC
Company Profile
Business description
Orthocell Ltd is engaged in the development, manufacture and commercialisation of collagen-based medical devices and cell therapies for the repair and regeneration of bone, nerve, tendon and cartilage defects. It has one segment regenerative medicine industry in Australia with products sold in Australia and internationally. Its solutions are Remplier, Striate, and Cell Therapies.
Contact
161 Campus Drive
Level 2, Murdoch University
Murdoch
PerthWA6150
AUST: +61 893602888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
Our fair value is above the IPO range, but outcomes could differ widely.
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Several gaming shares are trading at a discount to our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.60 | 95.80 | -1.07% |
| CAC 40 | 8,125.88 | 20.95 | -0.26% |
| DAX 40 | 25,682.69 | 53.55 | -0.21% |
| Dow JONES (US) | 50,236.28 | 38.11 | 0.08% |
| FTSE 100 | 10,512.82 | 38.35 | -0.36% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 24,868.01 | 438.13 | 1.79% |
| Nikkei 225 | 59,444.21 | 419.93 | 0.71% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,396.41 | 72.78 | 0.99% |
| S&P/ASX 200 | 8,730.40 | 91.40 | -1.04% |
| SSE Composite Index | 3,577.62 | 10.21 | -0.28% |